Study of Oral Piritrexim for Metastatic Breast Cancer
Author Information
Author(s): E.G.E. de Vries, J.A. Gietema, P. Workman, J.E. Scott, A. Crawshaw, H.J. Dobbs, I. Dennis, N.H. Mulder, D. Th. Sleijfer, P.H.B. Willemse
Primary Institution: University Hospital Groningen
Hypothesis
Can oral piritrexim be an effective treatment for metastatic breast cancer?
Conclusion
Orally administered piritrexim shows little activity in patients with locally advanced or metastatic breast cancer.
Supporting Evidence
- One patient achieved a partial response lasting for 24 weeks.
- Three patients had stable disease during 12 weeks of treatment.
- Seventeen patients had progressive disease.
Takeaway
This study tested a new medicine called piritrexim to see if it helps people with advanced breast cancer, but it didn't work very well.
Methodology
Patients received 25 mg of piritrexim orally three times daily for four days, repeated weekly, with dose adjustments based on toxicity.
Limitations
The study had a small sample size and a low response rate.
Participant Demographics
All participants were female, aged 35 to 84, with a median age of 66.
Statistical Information
Confidence Interval
0 to 24%
Want to read the original?
Access the complete publication on the publisher's website